MARKET

FNCH

FNCH

Finch Therapeutics Group, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.680
-0.100
-3.60%
Closed 16:00 06/29 EDT
OPEN
2.790
PREV CLOSE
2.780
HIGH
2.820
LOW
2.630
VOLUME
46.10K
TURNOVER
84.42K
52 WEEK HIGH
17.39
52 WEEK LOW
1.712
MARKET CAP
127.46M
P/E (TTM)
-1.8517
1D
5D
1M
3M
1Y
5Y
Finch Therapeutics to Participate in Upcoming June Investor Conferences
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class o...
GlobeNewswire · 06/02 11:00
BRIEF-Finch Therapeutics Group Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
reuters.com · 05/24 22:35
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of...
GlobeNewswire · 05/17 12:00
Finch Therapeutics GAAP EPS of -$0.52, revenue of $0.35M
Finch Therapeutics press release (NASDAQ:FNCH): Q1 GAAP EPS of -$0.52. Revenue of $0.35M. Susan Graf appointed board chair and Howard Franklin chief medical officer. Shares +3.59%.
Seekingalpha · 05/16 13:39
Finch Therapeutics Group Q1 EPS $(0.52) Up From $(1.00) YoY, Sales $354.00K Down From $3.55M YoY
Finch Therapeutics Group (NASDAQ:FNCH) reported quarterly losses of $(0.52) per share. This is a 48 percent increase over losses of $(1.00) per share from the same period last year. The company reported $354.00 thousand
Benzinga · 05/16 11:14
-- Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Reports Q1 Revenue $354,000
MT Newswires · 05/16 07:19
Better Therapeutics, Great Elm top healthcare gainers; TherapeuticsMD, Sutro Biopharma lead losers' pack
Gainers: Better Therapeutics (BTTX) +34%. Great Elm (GEG) +9%. Nuvectis Pharma (NVCT) +8%. Viatris (VTRS) +5%. BioNTech (BNTX) +3%. Losers: TherapeuticsMD (TXMD) -30%. Sutro Biopharma (STRO) -12%. NanoViricides (NNVC) -12%. RedHill Biopharma (RDHL) -10%. F...
Seekingalpha · 05/09 14:02
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of...
GlobeNewswire · 05/09 12:22
More
No Data
Learn about the latest financial forecast of FNCH. Analyze the recent business situations of Finch Therapeutics Group, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FNCH stock price target is 13.67 with a high estimate of 17.00 and a low estimate of 11.00.
High17.00
Average13.67
Low11.00
Current 2.680
EPS
Actual
Estimate
-0.80-0.60-0.40-0.20
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 53
Institutional Holdings: 10.68M
% Owned: 22.45%
Shares Outstanding: 47.56M
TypeInstitutionsShares
Increased
9
62.29K
New
3
2.33K
Decreased
19
254.24K
Sold Out
2
12.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.62%
Key Executives
Non-Executive Chairman/Independent Director
Susan Graf
President/Chief Executive Officer/Director
Mark Smith
Chief Financial Officer/Chief Operating Officer
Marc Blaustein
Senior Vice President
Howard Franklin
Chief Technology Officer
Bryan Gillis
Executive Officer
Michelle Rose
Other
Alka Batycky
Other
Zain Kassam
Secretary
Joseph Vittiglio
Independent Director
Domenic Ferrante
Independent Director
Nicholas Haft
Independent Director
Samuel Hamood
Independent Director
Christian Lange
Independent Director
Christopher Shumway
Independent Director
Jeffery Smisek
Independent Director
Jo Viney
No Data
No Data
About FNCH
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The Company’s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Its lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). It is also advancing CP101 for the treatment of chronic hepatitis B virus (HBV) Its product pipeline includes FIN-524, FIN-525, and FIN-211.

Webull offers kinds of Finch Therapeutics Group Inc stock information, including NASDAQ:FNCH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FNCH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FNCH stock methods without spending real money on the virtual paper trading platform.